Winners ECNP Travel Awards 2016

Winners ECNP Travel Awards at the 29th ECNP Congress 2016, Vienna, Austria

View the abstracts and posters here.

P.1 Basic and clinical neuroscience

P.1.a.025 New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: results of high-density imputation
Chiara Fabbri, Italy

P.1.a.038 BDNF gene variant Val66Met and personality predict future stressful life events: a longitudinal study
Kelli Lehto, Estonia

P.1.b.002 Activation of D1 and D2-expressing neurons in the nucleus accumbens enhances motivation
Carina Soares-Cunha, Portugal

P.1.c.005 Effect of smoking on frontal cortical thickness: a longitudinal study in participants with a history of attention-deficit/hyperactivity disorder and healthy controls
Sophie Akkermans, the Netherlands

P.1.c.009 Mitochondrial biogenesis is a rate limiting-factor for axonal growth
Merle Mandel, Estonia

P.1.c.014 The analysis of neurodevelopmental disorders by the generation of 3D cerebral organoids mimicking the human cerebral development
Matthias Jung, Germany

P.1.f.013 Study of the level of IgG to myelin basic protein and their catalytic activity in schizophrenic patients
Daria Parshukova, Russia

P.1.g.036 Monoamine transporter and receptor interaction profiles of novel phenethylamine derivatives
Dino Luethi, Switzerland

P.1.g.051 Boosting glutamatergic neurotransmission in infralimbic - but not prelimbic - cortex evokes antidepressant-like responses in rats through AMPA receptor activation
Júlia Gasull-Camós, Spain

P.1.g.092 Early functional changes induced by overexpression of α-synuclein in monoamine neurons: new therapies for Parkinson's disease using antisense oligonucleotides
Diana Alarcon Aris, Spain

P.1.g.093 Ketamine promotes plasticity in mouse-primary and human-iPSC-derived dopaminergic neurons via D3R and mTOR signalling
Laura Cavalleri, Italy

P.1.h.044 Attaining in vivo selectivity of positive modulation of GABAA α3 receptors in rats: a hard task
Bojan Batinic, Serbia

P.1.h.057 Rac1 GTPase and PAK activities in lateral amygdala constrain fear memory formation
Aniruddha Das, Israel

P.1.i.018 Abnormalities in the effective connectivity of thalamocortical circuitry in schizophrenia
Sarina Iwabuchi, United Kingdom

P.1.i.022 Individualised prediction of body mass index (BMI) by means of structural imaging data
Nils Opel, Germany

P.1.i.025 Subclinical non-emotional ADHD symptoms are related to smaller caudal anterior cingulate cortex volume and higher impulsiveness
Frida Bayard, Sweden

P.1.i.049 A European multicentric voxel based morphometry (VBM) study on schizophrenia and bipolar disorder
Eleonora Maggioni, Italy

P.1.j.009 The emotional processing network at the onset of social anxiety disorder: a combined diffusion tensor imaging and functional connectivity study
Laura Muzzarelli, Italy

P.1.j.011 Anterior cingulate serotonin 1B receptor binding is positively associated with inhibitory control and amygdala reactivity to aversive faces
Hjordt Liv Vadskjær, Denmark

P.2 Affective disorders and antidepressants 
P.2.a.019 Effects of antidepressant treatment with escitalopram on hippocampal structure and connectivity - a longitudinal study
Ulrich Rabl, Austria

P.2.b.056 Modafinil improves spatial working memory in patients with remitted depression
Muzaffer Kaser, United Kingdom

P.2.b.067 Towards an understanding of depression-associated gut microbiota induced neurobehavioural changes in the rat
John Richard Kelly, Ireland

P.2.e.012 Fluoxetine treatment affects the inflammatory response according to the quality of the living environment
Silvia Poggini, Italy

P.2.e.014 Selective siRNA-mediated suppression of astroglial glutamate transporters in infralimbic cortex induces depressive-like behaviors in mice
Maria Neus Fullana Llinàs, Spain

P.2.f.009 Antidepressant augmentation and co-initiation treatment in acute major depressive disorder: a systematic review, meta-analysis and metaregression analysis
Britta Galling, Germany

P.2.f.020 One-week administration of escitalopram decreases neural responses to self-referential processing in major depression
Emma Komulainen, Finland

P.2.f.030 Side effects breaking the blind does not explain the antidepressant effects of the selective serotonin reuptake inhibitors
Hieronymus Fredrik, Sweden

P.3 Psychotic disorders and antipsychotics
P.3.a.007 Disturbed DISC1 pathway interacts with adolescent cannabis exposure to produce impaired recognition memory restored by BDNF over-expression: a host-environment mouse model of severe mental illness
Ran Barzilay, Israel

P.3.b.047 Rich club organization of the connectome in children at familial high risk for schizophrenia and bipolar disorder
Guusje Collin, The Netherlands

P.3.d.056 Treatment strategies in case of non-response in schizophrenia: increasing the antipsychotic dose or switching the antipsychotic drug versus continuation of the same antipsychotic dose or drug
Myrto Samara, Germany

P.3.f.002 Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia, results from the multicentre FACE-SZ dataset
Guillaume Fond, France

P.3.f.018 The influence of a muscarinic M1 receptor antagonist on brain choline levels in patients with a psychotic disorder and healthy controls
Wilhelmina A.M. Vingerhoets, The Netherlands

P.3.f.031 Determinants of treatment response in first episode psychosis: a prospective 18F-DOPA PET study
Sameer Jauhar, United Kingdom

P.4 Anxiety disorders and anxiolytics
P.4.a.002 Hypomethylation of corticotropin releasing hormone receptor 1 promoter region: Converging evidence for a role in panic disorder
Christoph Schartner, Germany

P.4.a.014 Anxiogenic effects upon disruption of neuronal nitric oxide synthase postsynaptic density protein 95/discs large 1/zona occludens 1 (PDZ) interaction
Esin Candemir, Germany

P.4.b.019 DNA methylation signatures of susceptibility to panic disorder
Stella Iurato, Germany

P.4.b.020 Biological profiling of plasma neuropeptide Y in relation to posttraumatic stress symptoms in two combat cohorts
Alieke Reijnen, The Netherlands

P.4.e.004 Acute ketamine restores deficits in glutamate release and related molecular mechanisms induced by chronic mild stress in vulnerable rats
Paolo Tornese, Italy

P.5. Dementia and neurological disorders
P.5.a.001 MicroRNAs modulation: a new therapeutic approach for Alzheimer's disease
Ana Viegas, Portugal

P.5.b.003 Behavioural and psychological symptoms of dementia in Down syndrome: European development of the novel BPSD-DS evaluation scale
Alain Dekker, the Netherlands

P.5.c.009 Neurogenesis in the hippocampal dentate gyrus of a Down syndrome model can be restored by neonatal treatment with an agonist of the BDNF TrkB receptor
Fiorenza Stagni, Italy

P.5.c.016 Exploring the use of antisense oligonucleotides as therapy for C9ORF72-linked amyotrophic lateral sclerosis
Jorge Gomez, United Kingdom

P.6. Addiction
P.6.a.005 Administration of cannabidiol reduced reinforcement, motivation and relapse to alcohol
Adrián Viudez, Spain

P.6.c.015 The mGlu7 receptor: a new target in the therapy of cocaine and opiates addiction?
Zuzana Hajasova, France

P.6.c.023 GABAB receptor positive allosteric modulator Rac-BHFF normalizes VTA neuroadaptations and self-administrations of cocaine and ethanol in mice
Elena Vashchinkina, Finland

P.6.d.009 Altered grey matter co-variance in stimulant-dependent individuals: a graph-theory analysis
Gabriel Greening, United Kingdom

P.6.d.014 Endogenous opioid blockade modulates neural networks implicated in attentional and behavioural control in individuals recovering from alcohol and drug dependence
Tsen Vei Lim, United Kingdom

P.7 Child and adolescent disorders and treatment 
P.7.a.003 Subcortical brain volume development over age in autism spectrum disorder: results from the ENIGMA-ASD working group
Daan van Rooij, The Netherlands

P.7.a.004 Adolescent conduct problems related to white matter connectivity
Sanne Oostermeijer, The Netherlands

P.7.b.017 Disorganized amygdala networks in conduct-disordered juvenile offenders with callous-unemotional traits
Moji Aghajani, The Netherlands

P.8 Other topics